Temasek-backed Pavilion Capital backs funding in AI biopharma firm Insilico

Insilico Medicine

Pavilion Capital, a subsidiary of Singapore’s Temasek Holdings, has participated in the latest strategic funding round in US-headquartered artificial intelligence biopharma company Insilico Medicine. The funding amount was not disclosed.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at